Valuation: Jazz Pharmaceuticals plc

Market Cap 13.31B 11.94B 11.04B 10B 18.68B 1,268B 18.91B 132B 52.58B 663B 49.95B 48.9B 2,106B P/E 2026 *
21.1x
P/E 2027 * 12.6x
Enterprise Value 15.56B 13.96B 12.9B 11.69B 21.83B 1,481B 22.1B 154B 61.45B 775B 58.37B 57.14B 2,461B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 2.72x
Free-Float
96.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-3.26%
Current month-11.43%
1 month-13.94%
3 months-20.19%
6 months+0.53%
Current year+20.62%
1 week 202.3
Extreme 202.3
216.43
1 month 202.3
Extreme 202.3
238.87
Current year 156.95
Extreme 156.95
266.38
1 year 128.8
Extreme 128.8
266.38
3 years 95.49
Extreme 95.49
266.38
5 years 95.49
Extreme 95.49
266.38
10 years 86.88
Extreme 86.88
266.38
Manager TitleAgeSince
Chief Executive Officer 54 10/08/2025
Director of Finance/CFO 62 29/02/2024
Chief Tech/Sci/R&D Officer 54 31/07/2023
Director TitleAgeSince
Chairman 62 28/02/2003
Director/Board Member 65 17/01/2012
Director/Board Member 66 31/12/2009
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Sell

Chief Executive Officer

-2,000 0.0031%
01/10/26 Sell

Founder

-6,000 0.0092%
10/09/26 Sell

General Counsel

-1,200 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-3.26%+48.45%+62.66% 13.42B
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.06%+0.43%+41.42%+75.03% 404.1B
Weighted average by Cap. +0.25%+0.69%+44.51%+88.93%

Financials

2026 *2027 *
Net sales 4.73B 4.24B 3.92B 3.55B 6.63B 450B 6.71B 46.86B 18.67B 235B 17.73B 17.36B 748B 4.99B 4.48B 4.14B 3.75B 7B 475B 7.09B 49.49B 19.71B 249B 18.73B 18.33B 789B
Net income 635M 569M 526M 477M 891M 60.44B 902M 6.29B 2.51B 31.63B 2.38B 2.33B 100B 1.13B 1.02B 939M 850M 1.59B 108B 1.61B 11.22B 4.47B 56.4B 4.25B 4.16B 179B
Net Debt 2.24B 2.01B 1.86B 1.69B 3.15B 214B 3.19B 22.25B 8.86B 112B 8.42B 8.24B 355B 245M 220M 203M 184M 344M 23.34B 348M 2.43B 968M 12.21B 920M 900M 38.78B
Projected Income Statement - Annual - Jazz Pharmaceuticals plc
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
28/10/26 US$205.06 -0.83% 816,104
27/10/26 US$206.78 +0.53% 605,813
26/10/26 US$205.70 -3.88% 970,043
23/10/26 US$214.00 -0.30% 560,601
22/10/26 US$214.65 +1.26% 783,806
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Jazz Pharmaceuticals plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
205.06USD
Average target price
295.36USD
Spread / Average Target
+44.04%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jazz Pharmaceuticals plc
  1. Stock Market
  2. Stocks
  3. JAZZ Stock